For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Attruby represents a true change. These groundbreaking therapies preserve the transthyretin protein, slowing its damaging build-up and lessening the severity of the condition . People are now reporting improvements in their